Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
Status: | Completed |
---|---|
Conditions: | Infectious Disease |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 10 - 19 |
Updated: | 9/26/2018 |
Start Date: | December 1, 2014 |
End Date: | June 11, 2015 |
A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.
This is extension of the V102_16 study (NCT02140762). V102_16E1 is designed to assess the
effectiveness of a 3-dose vaccination series of MenABCWY, administered according to 0, 2, 6
month schedule, against the same panel of endemic US N. meningitidis serogroup B strains, as
measured by enc-hSBA assay. The subjects who completed the parent V102_16 study will be
invited at the time of their last study visit to participate in this extension study.
effectiveness of a 3-dose vaccination series of MenABCWY, administered according to 0, 2, 6
month schedule, against the same panel of endemic US N. meningitidis serogroup B strains, as
measured by enc-hSBA assay. The subjects who completed the parent V102_16 study will be
invited at the time of their last study visit to participate in this extension study.
Inclusion Criteria:
- Adolescents who completed V102_16 study and received the study vaccines as assigned in
the protocol (either two doses of the MenABCWY or one dose each of MenACWY and
Placebo).
Exclusion Criteria:
- Serious, acute, or chronic illnesses. Previous or suspected disease caused by N.
meningitidis.
- History of any meningococcal vaccine administration other than vaccination given in
the parent V102_16 protocol.
We found this trial at
8
sites
Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials
